{"preliminary_commentary":{"by_channel":{"x_thread":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04964479\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["benmelstobart","anlotinib"]],"indication":"PD-L1-positive advanced non-small-cell lung cancer","name":"CAMPASS","nct_id":"NCT04964479","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=campass-nct04964479. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"TQB2450 injection: once every 3 weeks, 1200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.\n\nAnlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur.","label":"TQB2450 injection + Anlotinib Hydrochloride capsules","type":"EXPERIMENTAL"},{"description":"Pembrolizumab injection: once every 3 weeks, 200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.\n\nPlacebo of Anlotinib hydrochloride capsules:once a day, 0mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur.","label":"Pembrolizuma injection + placebo of Anlotinib hydrochloride capsules","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2023-03","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer"],"enrollment":{"count":375,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"TQB2450 injection","otherNames":[],"type":"DRUG"},{"name":"Anlotinib Hydrochloride Capsules","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab injection","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2021-08-20","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","official_title":"A Randomized, Blind, Parallel Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Pembrolizumab Injection as a First-line Treatment on Patient With Advanced NSCLC.","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2022-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease progression-free survival(PFS) evaluated by Independent Review Committee (IRC)","timeFrame":"Baseline to up to two years"}],"references":[{"citation":"Zhong H, Wang J, Yang R, Luo Y, Zuo W, Zhang W, Xie C, Li Q, Liu Q, Xu X, Wang Q, Yu Y, Chen Y, Yi T, Min X, Shi J, Yang J, Sun H, Chen H, Shi H, Gao J, Shi J, Zhang B, Chu T, Li K, Han B; CAMPASS Investigators. Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial. Lancet Oncol. 2026 Apr;27(4):419-431. doi: 10.1016/S1470-2045(26)00049-5. Epub 2026 Mar 10.","pmid":"41825453","type":"DERIVED"},{"citation":"Zhang W, Wang J, Wang Q, Cheng Y, Yang L, Li Y, Zhong H, Chu T, Dong Y, Zhang Y, Qian F, Xiong L, Shi C, Zhang C, He Z, Zhu J, Liu X, Ma H, Li K, Han B. A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer. Lung Cancer. 2023 Oct;184:107353. doi: 10.1016/j.lungcan.2023.107353. Epub 2023 Aug 21.","pmid":"37647728","type":"DERIVED"}],"start_date":{"date":"2021-08-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)","url":"https://clinicaltrials.gov/study/NCT04964479"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/campass-nct04964479"}